Rankings
▼
Calendar
ADMA
ADMA Biologics, Inc.
$4B
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$118M
+59.1% YoY
Gross Profit
$63M
53.9% margin
Operating Income
$38M
32.6% margin
Net Income
$112M
95.2% margin
EPS (Diluted)
$0.46
QoQ Revenue Growth
-1.9%
Cash Flow
Operating Cash Flow
$50M
Free Cash Flow
$47M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$489M
Total Liabilities
$140M
Stockholders' Equity
$349M
Cash & Equivalents
$103M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$118M
$74M
+59.1%
Gross Profit
$63M
$31M
+103.7%
Operating Income
$38M
$14M
+169.3%
Net Income
$112M
-$18M
+734.2%
Revenue Segments
ADMA BioManufacturing Segment
$116M
99%
Plasma Collection Centers Segment
$804,000
1%
Geographic Segments
United States
$115M
98%
International
$3M
2%
← FY 2024
All Quarters
Q1 2025 →
ADMA Q4 2024 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena